Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Human Microbiome Market to Reach $6.08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics Finds Frost & Sullivan - Human microbiome therapeutics to find high application in cancer immunotherapies and personalized medication, finds Frost & Sullivan - Frost.com
Human Microbiome Market to Reach $6.08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics Finds Frost & Sullivan

 

PRZOOM - /newswire/ - Santa Clara, CA, United States, 2019/12/11 - Human microbiome therapeutics to find high application in cancer immunotherapies and personalized medication, finds Frost & Sullivan - Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

There has been a surge in industry-academia collaborations in the human microbiome therapeutics space. The partnerships between pharma/biotech companies and academic institutes are bringing together the research expertise of educational organizations and the marketing acumen of businesses to clear paths to commercialization. These collaborations are expected to utilize the data collected by direct-to-consumer microbiome testing (DTCMT) for drug discovery. The market is forecast to grow from $4.48 billion in 2018 to $6.07 billion in 2023, at a compound annual growth rate (CAGR) of 6.30%.

“DTCMT companies are anticipated to partner with probiotics manufacturers to develop customized probiotics for more targeted therapies,” said Unmesh Lal, Program Manager, Transformational Health. “As there are no technical development components for live biotherapeutic products (LBPs), certain microbiome therapies will have a quicker path to commercialization.”

Frost & Sullivan’s recent analysis, Growth Opportunities in Human Microbiome Market, Forecast to 2023, assesses the opportunities available and forecasts the future of the market using a strategic options framework. It covers the market segments of over-the-counter (OTC), therapeutics, and diagnostics and examines the changes that need to be made to business models to adapt to market conditions.

“The rise in public-private partnerships (PPP), especially in the developing countries, will fuel the development of novel human microbiome therapeutics,” noted Lal. “The next phase of drugs that will be introduced after 2020 could be in the space of metabolic conditions like T2D. In the meantime, there will be considerable traction in the areas of screening and diagnostics. These sequencing and data-driven services are likely to be adopted by both academic institutes and other therapeutic manufacturers.”

For additional growth opportunities, pharmas will be looking to:

• Focus on microbiome-based cancer immunotherapies. With the rise in demand, there are clear opportunities for new biotechs to enter the market.
• Develop personalized therapy, be it based on the administrations of targeted microbial nutrients (precision prebiotics), specific microbial cocktails, targeted antibiotics, and phages or personalized dietary interventions.
• Gain awareness about the US Food & Drug Administration (FDA) regulations to perform pre-market evaluations to identify if similar DNA-based genetic test kits are available.
• Ensure contract manufacturing organizations (CMOs) have in place good laboratory practices (GLPs) and specific manufacturing capabilities to develop prebiotics, probiotics, and microbiome drugs.

Growth Opportunities in Human Microbiome Market, Forecast to 2023 is part of Frost & Sullivan’s global Life Sciences Growth Partnership Service program.

About Frost & Sullivan

For over five decades, Frost & Sullivan (frost.com) has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Growth Opportunities in Human Microbiome Market, Forecast to 2023 / MECA-52

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Human Microbiome Market to Reach $6.08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Human Microbiome | Frost & Sullivan
Contact: Mariana Fernandez - Frost.com 
210-348-1012 mariana.fernandez[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®
Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  JobsWare.com

Visit  Limelon Advertising, Co.

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2020 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today